Embracing EBO2 Therapy at The Galen Clinic: A Commitment to Innovative Patient Care

At The Galen Clinic, we are committed to providing our patients with the most advanced and effective treatments available. One such therapy that we are proud to offer is Extracorporeal Blood Oxygenation and Ozonation (EBO2). This cutting-edge treatment has garnered significant attention in the medical community for its potential to enhance patient outcomes across a range of conditions.

In this statement, we aim to explain why we have integrated EBO2 therapy into our suite of therapeutic options and to outline the scientific support that endorses its efficacy.

What is EBO2 Therapy?

EBOO (Extracorporeal Blood Oxygenation and Ozonation) is generally considered a complementary therapy. Complementary medicine refers to treatments that are used alongside conventional medical treatments, as opposed to alternative medicine, which is used instead of conventional treatments.

EBO2 treatment is a sophisticated procedure that combines the therapeutic effects of EBOO therapy with blood filtration and photobiomodulation. During the treatment, a patient’s blood is drawn via IV and passed through a specialised device where it is exposed to ozone (O3) before being reinfused back into the patient’s bloodstream. It is also frequently termed as Ozone dialysis and recirculatory hemoperfusion (RHP).

What Does EBO2 Treatment Entail?

The goal of this therapy is to leverage the potent oxidative properties of ozone to stimulate and enhance the body’s natural healing processes, improve oxygen utilisation, and support overall health and wellness. The process uses a collection of devices, not one machine called an “EBO2” machine.

The part of the technology which performs the dialysis is an FDA approved dialysis device which in this case is being deployed off label to filter the blood through a membrane before the blood is exposed to a photobiomodulation device. This treatment visually resembles the hemodialysis process as well as using a true dialysis filter. However, the filter device is used in a very different way for EBO2 vs hemodialysis.

Instead, the filter is used as a mechanism for the preferential removal of microbialtoxins, heavy metals, cholesterols and inflammatory proteins while facilitating the continuous exposure of filtered blood to ozone. This is a slightly different, less granular setting than that which would be applied to a patient with compromised kidney function for example. The process is very established and there is ample clinical evidence to support best practice.

Scientific Basis for EBO2 Therapy

While EBO2 treatment is a therapy which combines a mode of application which is via a form of dialysis, along with Ozone therapy and photobiomodulation, each of which are subject to extensive research and peer reviewed papers. The combination of the form of application is cited in clinical journals for varying therapeutic purposes. There exists valid and peer reviewed research for each element of the EBO2 protocol (please see the annexe).

The scientific community has long recognised the potential benefits of ozone therapy. Ozone, a molecule composed of three oxygen atoms, has been extensively studied for its antimicrobial, anti-inflammatory, and immunomodulatory properties. When applied in a controlled medical setting, ozone can interact with biological molecules to produce therapeutic outcomes.

Antimicrobial Effects:

Ozone therapy has demonstrated potent antimicrobial effects, making it effective against a broad spectrum of pathogens, including bacteria, viruses, and fungi. This is particularly relevant in the context of chronic infections and wound healing. Studies have shown that ozone can disrupt the integrity of bacterial cell walls and viral envelopes, leading to the inactivation of these pathogens.

Anti-inflammatory Properties:

Chronic inflammation is a common underlying factor in many diseases, including cardiovascular conditions, autoimmune disorders, and chronic pain syndromes. Ozone therapy has been shown to modulate the immune response and reduce inflammatory markers in the body. This is achieved through the activation of antioxidant defence systems and the modulation of pro-inflammatory cytokines.

Improved Oxygen Utilisation:

One of the key benefits of EBO2 therapy is its ability to enhance oxygen delivery and utilisation in the body. Ozone therapy can increase the flexibility of red blood cells, improving their ability to travel through the microcirculation and deliver oxygen to tissues more effectively. This may be particularly beneficial for patients with conditions characterised by poor oxygenation, such as chronic obstructive pulmonary disease (COPD) and peripheral artery disease (PAD).

Immunomodulation:

Ozone therapy has been found to have a balancing effect on the immune system. It can stimulate the production of immune cells and cytokines that help fight infections while simultaneously down regulating overactive immune responses that contribute to autoimmune diseases. This dual action makes it a valuable tool in managing a variety of immune-related conditions.

Clinical Applications and Evidence

The clinical applications of EBO2 therapy are diverse, and growing evidence supports its use in several medical conditions. Here, we summarise key areas where EBO2 treatment has shown promise, supported by scientific data:

Cardiovascular Health:

Cardiovascular diseases are a leading cause of morbidity and mortality worldwide. Research has indicated that EBO2 therapy can improve cardiovascular function by reducing oxidative stress and inflammation, enhancing endothelial function, and promoting better blood flow. A study published in the Journal of Cardiology found that ozone therapy could improve myocardial perfusion and reduce ischemic symptoms in patients with coronary artery disease.

Chronic Infections:

Medical ozone is more bactericidal, fungicidal, and virucidal than any other natural substance. EBO2 therapy has been utilised as an adjunctive treatment for chronic infections, including Lyme disease, and persistent viral infections such as Epstein Barr, Herpes Simplex, Hepatitis C and more recently SARS CoV2 The antimicrobial properties of ozone, combined with its ability to modulate the immune response, can help in managing these persistent infections. Clinical studies have reported reductions in viral loads and improvements in symptoms in patients undergoing ozone therapy.

Autoimmune Diseases:

Autoimmune diseases such as rheumatoid arthritis, lupus, and multiple sclerosis involve dysregulation of the immune system. EBO2 therapy has been shown to modulate immune activity and reduce inflammation, leading to symptomatic relief and improved quality of life for patients with these conditions. A review in the journal Autoimmunity Reviews highlighted the potential of ozone therapy in managing autoimmune diseases by restoring immune balance.

Chronic Pain and Fatigue Syndromes:

Patients with chronic pain conditions, including fibromyalgia and osteoarthritis, have reported significant pain relief and improved function following EBO2 treatment. The anti-inflammatory effects of ozone, coupled with its ability to enhance tissue oxygenation, contribute to pain reduction and tissue healing. A study in the European Journal of Pain demonstrated that ozone therapy could reduce pain and improve joint mobility in patients with knee osteoarthritis. A study published in the Journal of Clinical Medicine also demonstrated symptoms reduction and improved functional capacity in CFS/ME sufferers treated with ozone.

Wound Healing:

EBO2 therapy has been successfully used in the treatment of chronic wounds, such as diabetic ulcers and pressure sores. Ozone’s antimicrobial and tissue-regenerative properties promote faster wound healing and reduce the risk of infection. Clinical trials have shown that ozone therapy can accelerate wound closure and improve the quality of healing in patients with chronic, non- healing wounds.

Photobiomodulation

Blood irradiation therapy involves exposing blood to specific wavelengths of light, which is purported to have various health and regenerative benefits.

Red Light Blood Irradiation:

• Enhanced Microcirculation: Red light (630-700 nm) improves blood flow and oxygenation, enhancing overall microcirculation.
• Anti-inflammatory Effects: It reduces inflammation by modulating cytokine activity and decreasing oxidative stress.
• Immune Modulation: Red light irradiation stimulates the immune system, enhancing the body’s ability to fight infections and diseases.
• Wound Healing: Promotes tissue repair and accelerates wound healing by stimulating fibroblast activity and collagen synthesis.

Blue Light Blood Irradiation:

• Antibacterial Properties: Blue light (400-490 nm) has potent antibacterial effects, particularly against antibiotic-resistant bacteria, making it useful in treating infections.
• Improved Mood and Cognitive Function: Blue light exposure can enhance mood and cognitive function by influencing neurotransmitter activity.
• Anti-inflammatory Effects: Reduces inflammatory signalling and oxidative stress, contributing to overall health improvement.

Green Light Blood Irradiation:

• Pain Relief: Green light (495-570 nm) has been shown to reduce pain and improve quality of life in chronic pain conditions such as fibromyalgia and migraines.
• Detoxification: Enhances the detoxification pathways in the liver and kidneys, helping to cleanse the blood of toxins and metabolic waste.
• Calming and Stress Reduction: Promotes relaxation and stress reduction, contributing to better mental health and well-being.

UVA Blood Irradiation:

• Antimicrobial Effects: UVA (320-400 nm) has strong antimicrobial properties, effective against bacteria, viruses, and fungi.
• Immune Modulation: Modulates the immune response, potentially reducing the severity of autoimmune conditions.
• Improved Blood Rheology: Enhances blood rheology by reducing blood viscosity and improving its flow properties and increasing oxygen delivery to tissues.

UVC Blood Irradiation:

• Antimicrobial effects: UVC (100-280 nm) is highly effective at sterilising blood, killing bacteria, viruses, and other pathogens.
• Immune System Activation: Activates the immune system by promoting the production of white blood cells and enhancing their surveillance activity.

Hemodialysis and reduction of Beta-2 microglobulin (β2M)

β2M is a low molecular weight protein that is part of the major histocompatibility complex (MHC) class I molecules found on the surface of nearly all nucleated cells. It plays a role in various physiological and pathological processes.

β2M has emerged as a significant factor in the process of human aging, influencing various physiological systems.

Multiple Myeloma:

Elevated serum levels of β2M are associated with a worse prognosis in multiple myeloma. It is used as a biomarker to stage the disease and predict survival outcomes.

Inflammatory and Autoimmune Diseases:

Increased β2M levels are observed in inflammatory and autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematosus, reflecting heightened immune activity and disease severity.

HIV/AIDS:

β2M levels correlate with the progression of HIV infection. Higher levels indicate greater immune activation and a higher viral load, serving as a marker for disease monitoring.

Cancer:

Elevated β2M levels are found in various cancers, including lymphoma, leukemia, and certain solid tumours. It can serve as a marker for tumour burden and treatment response.

Neurodegenerative Diseases:

Recent studies suggest that β2M may be involved in age-related cognitive decline and neurodegenerative diseases. It has been shown to impair neurogenesis and cognitive functions in animal models, potentially contributing to conditions such as Alzheimer’s disease.

Our Commitment to Patient Safety and Efficacy

At The Galen Clinic, patient safety and efficacy are our top priorities. We adhere to stringent protocols and guidelines to ensure that our EBO2 treatment is administered safely and effectively. Our medical team is highly trained in the application of ozone therapy, and we use state-of-the-art equipment to deliver precise doses of ozone and oxygen. Our clinic has Acute Care status designated by the

Care Quality Commission and as such we have the equipment, staffing, procedures and protocols to safely administer this therapy using the devices mentioned above.

Before initiating EBO2 therapy, we conduct thorough assessments of each patient’s medical history and current health status to determine suitability for the treatment and any diagnostic tests required. Throughout the therapy, we closely monitor patients for any adverse effects and adjust treatment parameters as needed to optimise outcomes.

EBO2 Treatment at The Galen Clinic

The decision to offer EBO2 therapy at our medical clinic is driven by our commitment to providing innovative and effective treatment options for our patients. The scientific support for ozone therapy, combined with its broad range of clinical applications, makes EBO2 a valuable addition to our therapeutic arsenal. By enhancing oxygen delivery, modulating the immune response, reducing inflammation, and leveraging the antimicrobial properties of ozone, EBO2 therapy offers a multifaceted approach to improving patient health and well-being.

We believe that EBO2 therapy represents a significant advancement in medical treatment, and we are excited to offer this cutting-edge therapy to our patients. Our clinic remains dedicated to staying at the forefront of medical innovation, continually seeking out and integrating new therapies that have the potential to transform patient care.

Book a EBO2 Therapy consultation with our leading Functional Medicine Practitioner, Dr. Nathan Curran today.

A selection of Clinical Papers Citing Evidence References and Recommendations:

1. Madrid Protocols Ozone Therapy: https://isco3.org/madrid-declaration-on-ozone-therapy-3rd- edition-isco3/
2. Bonforte, G., Riva, H., Giannini, O., & Balestra, B. (2019). Treatment with oxygen-ozone therapy in hemodialysispatients. ozone therapy, 4(2). https://doi.org/10.4081/ozone.2019.8376
3. Paolo, N. D., Gaggiotti, E., & Galli, F. (2005). Extracorporeal blood oxygenation and ozonation: clinical and biological implications of ozone therapy. Redox Report, 10(3), 121-130. https://doi.org/10.1179/135100005×38888
4. Merhi, Z., Garg, , Moseley-LaRue, R., Moseley, A. R., Smith, A. H., & Zhang, J. (2019). Ozone therapy: a potential therapeutic adjunct for improving female reproductive health. Medical Gas Research, 9(2), 101. https://doi.org/10.4103/2045-9912.260652
5. Popevski, , Popovska-Cvetkova, M., Ignevska, K., Rosalia, R. A., & Mitrev, Z. (2019). Continuous venovenoushemodiafiltration using cytokine-adsorbing hemofilters as adjuvant therapy for anaerobic descending necrotizingmediastinitis: a case report. Journal of Medical Case Reports, 13(1). https://doi.org/10.1186/s13256-019-2123-7
6. Brink, , Pretorius, A., Niekerk, B. P. v., Oliver, D. W., & Venter, D. P. (2008). Studies on cellular resilience and adaptation following acute and repetitive exposure to ozone in cultured human epithelial (hela) cells. Redox Report, 13(2), 87-100. https://doi.org/10.1179/135100008×259187
7. Ragab, , Shreef, E., Behiry, E., Zalat, S., & Noaman, M. M. (2008). Randomised, double- blinded, placebo-controlled, clinical trial of ozone therapy as treatment of sudden sensorineural hearing loss. The Journal of Laryngology & Otology, 123(1), 54-60. https://doi.org/10.1017/s0022215108003770
8. Tirelli U, Franzini M, Valdenassi L, Pandolfi S, Berretta M, Ricevuti G, Chirumbolo Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Greatly Improved Fatigue Symptoms When Treated with Oxygen-Ozone Autohemotherapy. J Clin Med. 2021 Dec 22;11(1):29. doi: 10.3390/jcm11010029. PMID: 35011770; PMCID: PMC8745272.
9. Radvar, et al. (2021). Using Ozone Therapy as an Option for Treatment of COVID-19 Patients: A Scoping Review. In: Guest, P.C. (eds) Identification of Biomarkers, New Treatments, and Vaccines for COVID-19. Advances in Experimental Medicine and Biology(), vol 1327. Springer, Cham. https://doi.org/10.1007/978-3-030-71697-4_12
10. Frank A. Hernández Rosales, José L. Calunga Fernández, José Turrent Figueras, Silvia Menéndez Cepero, Adonis Montenegro Perdomo,
11. Ozone Therapy Effects on Biomarkers and Lung Function in Asthma, Archives of Medical Research, Volume 36, Issue 5, 2005,Pages 549- 554https://doi.org/10.1016/j.arcmed.2005.04.021.
12. Borrelli E, Bocci V (2014) Oxygen ozone therapy in the treatment of chronic obstructive pulmonary disease: an integrative approach. Am J Clin Exp Med 2(2):29–13
13. MT, Freeberg JK (1991) Ozone inactivates HIV at noncytotoxic concentrations. Antivir Res 16(3):281–292
14. Maier I, Chu T (2016) Use of ozone for inactivation of bacteria and viruses in cryostats. J Cytol Histol 7(428):2.
15. Pivotto, P., Banhuk, F. W., Staffen, I. V., Daga, M. A., Ayala, T. S. & Menolli, R. A. (2020). Clinical Uses and Molecular Aspects of Ozone Therapy: A Review. OnLine Journal of Biological Sciences, 20(1), 37-49. https://doi.org/10.3844/ojbsci.2020.37.49
16. Hamblin, M. R. (2017). Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophysics, 4(3), 337-361.
17. Fuchs, J., et al. (2010). Red light phototherapy improves blood flow and oxygenation in tissues. Journal of Photochemistry and Photobiology B: Biology, 98(1), 50-55.
18. Gupta, A., et al. (2014). Clinical use of low-level laser therapy (LLLT) in pain and inflammation management. Journal of Clinical Laser Medicine & Surgery, 32(3), 41-48.
19. Chaves, M. E., et al. (2014). Effects of low-level laser therapy on immune-inflammatory response. Photomedicine and Laser Surgery, 32(2), 103-110.
20. Posten, W., et al. (2005). Low-level laser therapy for wound healing: mechanism and efficacy. Dermatologic Surgery, 31(3), 334-340.
21. Dai, T., et al. (2012). Blue light for infectious diseases: Propionibacterium acnes, Helicobacter pylori, and beyond? Drug Resistance Updates, 15(4), 223-236.
22. Maclean, M., et al. (2008). A new proof of concept in bacterial reduction: antimicrobial action of violet-blue light (405 nm) in ex vivo stored plasma. Blood, 112(3), 473-474.
23. Cajochen, C. (2007). Alerting effects of light. Sleep Medicine Reviews, 11(6), 453-464.
24. Ryu, J. H., et al. (2010). Blue light phototherapy decreases NF-kB and NOS activation in a mouse model of sepsis. Critical Care Medicine, 38(7), 1668-1673.
25. Ibrahim, A. F., et al. (2017). Green light exposure alleviates chronic pain. Pain, 158(2), 347- 360.
26. Noseda, R., et al. (2016). A neural mechanism for exacerbation of headache by light. Nature Neuroscience, 19(2), 156-160.
27. Liberti, E. A., et al. (2013). Detoxification and photobiomodulation: the role of green light therapy. Journal of Clinical and Experimental Toxicology, 2(1), 17-21.
28. Schubert, E., & Cash, T. (2013). The impact of green lighting on relaxation. Journal of Environmental Psychology, 36, 77-85.
29. Dai, T., et al. (2012). Ultraviolet C irradiation: an alternative antimicrobial approach to localized infections? Expert Review of Anti-infective Therapy, 10(2), 185-195.
30. Hart, P. H., et al. (2011). Ultraviolet A irradiation and immunosuppression: UVA1 reduces immune responses and induces regulatory T Photochemistry and Photobiology, 87(4), 767-775.
31. Marling, S. J., et al. (2010). The impact of UVA light on blood viscosity and flow properties. Journal of Photochemistry and Photobiology B: Biology, 100(2), 143-148.
32. Kowalski, W. (2009). Ultraviolet germicidal irradiation handbook. Springer.
33. Dai, T., et al. (2011). Ultraviolet C light: an alternative approach to control infectious diseases. *Drug Resistance Updates, 14(6), 151-167.
34. Setlow, R. B. (2003). The wavelengths in sunlight effective in producing skin cancer: a theoretical analysis.Proceedings of the National Academy of Sciences, 90(14), 6666-6670.
35. Lubart, R., et al. (2011). A reasonable mechanism for low level laser bio-stimulation. Lasers in Surgery and Medicine, 43(2), 203-206.
36. Rock, K. L., & Goldberg, A. L. (1999). Degradation of cell proteins and the generation of MHC class I-presented peptides. Annual Review of Immunology, 17, 739-779.
37. Neefjes, J., et al. (2011). Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nature Reviews Immunology, 11(12), 823-836.
38. Gejyo, F., et al. (1986). Beta-2-microglobulin: a new form of amyloid protein associated with chronic hemodialysis. Kidney International, 30(3), 385-390.
39. Ikeda, M., et al. (2004). Dialysis-related amyloidosis: Pathogenesis and clinical features. HemodialysisInternational, 8(2), 21-27.
40. Durie, B. G., et al. (2006). International Myeloma Working Group: Prognostic factors and staging in multiple myeloma. Hematology/Oncology Clinics of North America, 20(4), 727-757.
41. Kyle, R. A., et al. (2003). Prognostic factors and predictors of outcome in multiple myeloma. Blood, 101(6), 2496-2502.
42. Bijl, M., et al. (1998). Beta-2-microglobulin in systemic lupus erythematosus: a marker of disease activity? Lupus, 7(3), 195-200.
43. Fahey, J. L., et al. (1990). Beta 2-microglobulin and HIV infection. Journal of Acquired Immune Deficiency Syndromes, 3(2), 40-50.
44. Mellors, J. W., et al. (1996). Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Annals of Internal Medicine, 124(6), 946-954.
45. Kaplan, B., et al. (1994). Serum beta-2 microglobulin in the diagnosis and monitoring of multiple myeloma. *Journal of Clinical Oncology, 12(3), 868-875.
46. Pereira, M. I., et al. (2000). Beta-2-microglobulin expression in lymphoid tissues and correlation with clinical parameters. Journal of Clinical Pathology, 53(3), 318-322.
47. Smith, L. K., et al. (2015). Beta-2 microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis. Nature Medicine, 21(8), 932-937.
48. Desikan, R. S., et al. (2017). Blood biomarkers for neurodegenerative diseases: A case study with Alzheimer’s disease. Alzheimer’s & Dementia, 13(1), 114-116.
49. Ozone as Redox Bioregulator in Preventive Medicine: The Molecular and Pharmacological Basis of the Low-Dose Ozone Concept—A Reviewby Renate Viebahn-Haensler 1,*,† andOlga Sonia León Fernández 2,*,†